Gewinn- und Verlustrechnung von Agios Pharmaceuticals, Inc.

Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% YoY, with strong payer coverage and operational leverage emerging. AGIO's $965M cash position supports pipeline expansion and mitigates near-term dilution risk ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 103,955 shares of the biopharmaceutical company's stock after acquiring an additional 36,802 shares during the quarter. Assenagon

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals NASDAQ: AGIO reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease approval later this year.